52. ASCO 2023 - Plenary Session

Theodore Roosevelt is famously quoted saying: "It is hard to fail, but it is worse never to have tried to succeed." This is what ASCO, oncologists and cancer researchers are faced with daily. As our tour de force of ASCO 2023 ends, and we foresee a future where daily episodes don't arrive, we present our final episode. Michael and Josh have kept three of the most exciting trials until the end.

Today, three plenary sessions are reviewed. The first is in gliomas, the second in adjuvant lung cancer treatment, and finally, Michael and Josh tackle Mount Everest and the confusing world of rectal cancer with PROSPECT, a trial looking at non-inferiority and toxicity.

Studies

INDIGO: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA1

ADAURA: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA3?af=R

PROSPECT: https://meetings.asco.org/abstracts-presentations/219804

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.